Barriers to Access Do Not Fully Explain Disparities in Ovarian Cancer Treatment
Non-Hispanic Black patients are less likely than Hispanic or non-Hispanic White patients to receive guideline-recommended treatment for ovarian cancer.
Ovarian Cancer
Prolonging Bevacizumab Treatment Does Not Improve PFS or OS in Ovarian Cancer
Fifteen months of bevacizumab should remain the standard for patients with ovarian cancer receiving chemotherapy after cytoreductive surgery, researchers say.
Elahere Granted Accelerated Approval for Platinum-Resistant Ovarian Cancer
The approval was based on data from the SORAYA trial.
GSK: Zejula Use for Second-Line Maintenance Treatment Restricted
The decision to restrict the indication follows an FDA review of the phase 3 ENGOT-OV16/NOVA trial.
ROCA Surveillance of Women With BRCA1/2 Mutations Feasible in Real World
Ovarian cancer surveillance using the Risk of Ovarian Cancer Algorithm (ROCA) is effective in the real world, a study suggests.
MYC Inhibitor Can Stave Off Progression in Patients With Advanced Solid Tumors
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
Underrepresentation in Cancer Trials May Not Be Driven by Ineligibility
Black and White patients were similarly likely to be eligible for cancer trials and to be offered enrollment.
Bevacizumab Biosimilar Alymsys Now Available
Alymsys (bevacizumab-maly), a biosimilar to Avastin (bevacizumab), has been made available by Amneal Pharmaceuticals.
ASCO Updates Guidelines for PARP Inhibitors in Ovarian Cancer
The update was prompted by data from phase 3 trials showing positive and negative results with PARP inhibitors.
Sexual Dysfunction May Be Common Among Women With Cancer
In a cohort of nearly 700 women with cancer, more than 60% reported some type of sexual dysfunction.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...